

【NEWS RELEASE】

June 20, 2025

Sumitomo Mitsui Banking Corporation

Investment in AN Venture Partners I, LP

Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, hereinafter "SMBC") has entered into an investment agreement with AN Venture Partners I, LP (hereinafter the "Fund"), which is operated by ANV Management, LLC (hereinafter "ANV"), which invests in the biotechnology field.

ANV was established in 2022 with the aim of creating global biotechnology companies based primarily on the excellent research and drug discovery seeds of universities, research institutions and companies in Japan.

ANV is run by venture capitalists and experts from pharmaceutical companies with a high level of knowledge and experience in the field. Underpinned by its extensive network with academia and a deep understanding of drug discovery seeds, ANV supports the social implementation of excellent biotechnologies through entrepreneurship related to research with great social significance.

In addition, under an alliance with ARCH Venture Partners, leading venture capital firm in the global biotechnology field, ANV provides access to the U.S. startup ecosystem and can hire talented management personnel to accelerate the process from R&D and clinical trials to a global market launch.

In the medium term, the aim is that technology and capital cultivated through social implementation in the U.S. will be returned to the biotechnology ecosystem in Japan, leading to the growth of biotechnology in Japan.

Sumitomo Mitsui Financial Group, Inc. (President & Group CEO: Toru Nakashima) has set "Create social value" as one of the basic policies in its current Mid-Term Management Plan and designated "Japan's Regrowth" as one of its priority issues. In addition, the "Social Value Creation Investment Fund" (*1) has been established as a framework to support the co-creation and development of businesses with customers and the development of new technologies and industries which contribute to the creation of social value through risk-taking.

The drug discovery industry is positioned as a growth industry by the Japan government, and private investment in start-up companies from academia with new technologies and cutting-edge knowledge, mainly in biopharmaceuticals, is expected. By utilizing the Social Value Creation Investment Fund for an LP investment in the Fund, we will contribute to "Japan's regrowth" through the expansion of the drug discovery ecosystem in Japan.

[Reference] Overview of ANV Management, LLC

Company Name	ANV Management, LLC
Establishment	2022
Location	Tokyo, USA (San Francisco)

*1 Social Value Creation Investment Fund

This investment framework was established for the purpose of supporting the co-creation and development of businesses with customers and the development of new technologies and industries which contribute to the creation of social value through risk-taking. The scope of investment has been expanded from that under the former “Sustainability Investment Fund” to cover the five priority issues that SMBC Group should proactively address: “Environment,” “DE&I/Human Rights,” “Poverty & Inequality,” “Declining Birthrate & Aging Population” and “Japan’s Regrowth.” The maximum investment amount of the fund for FY2025 is set at 50 billion yen, an increase of 10 billion yen from the previous fiscal year.

[Reference] Press Release on the Establishment of the Social Value Creation Investment Fund

"Establishment of Expense Budget for Creation of Social Values" (dated May 17, 2024)

(https://www.smfg.co.jp/news_e/pdf/e20240517_01.pdf)

END